Overview Myasthenia Gravis Inebilizumab Trial Status: Recruiting Trial end date: 2024-12-28 Target enrollment: Participant gender: Summary Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension. Phase: Phase 3 Details Lead Sponsor: Viela Bio